{"drugs":["Velaglucerase Alfa","VPRIV"],"mono":{"0":{"id":"929595-s-0","title":"Generic Names","mono":"Velaglucerase Alfa"},"1":{"id":"929595-s-1","title":"Dosing and Indications","sub":[{"id":"929595-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Non-neuropathic Gaucher's disease, chronic:<\/b> (treatment-naive) 60 units\/kg IV infusion over 60 minutes every other week; adjust dose based on therapeutic goals and response to therapy<\/li><li><b>Non-neuropathic Gaucher's disease, chronic:<\/b> (switching from imiglucerase) starting 2 weeks following the last imiglucerase dose, initiate velaglucerase at previous imiglucerase dose; infuse dose over 60 minutes every other week; adjust dose based on therapeutic goals and response to therapy<\/li><\/ul>"},{"id":"929595-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Non-neuropathic Gaucher's disease, chronic:<\/b> (4 to 17 years of age) treatment-naive, 60 units\/kg IV infusion over 60 minutes every other week; adjust dose based on therapeutic goals and response to therapy<\/li><li><b>Non-neuropathic Gaucher's disease, chronic:<\/b> (4 to 17 years of age) starting 2 weeks following the last imiglucerase dose, initiate velaglucerase at previous imiglucerase dose; infuse dose over 60 minutes every other week; adjust dose based on therapeutic goals and response to therapy<\/li><\/ul>"},{"id":"929595-s-1-6","title":"Dose Adjustments","mono":"<b>infusion reaction:<\/b> slow, interrupt, or discontinue infusion; resume at extended infusion time "},{"id":"929595-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Non-neuropathic Gaucher's disease, chronic<br\/>"}]},"3":{"id":"929595-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929595-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"929595-s-3-10","title":"Precautions","mono":"<ul><li>hypersensitivity reactions have been reported<\/li><li>infusion-related reactions including headache, dizziness, hypotension, hypertension, nausea, fatigue, and asthenia have been reported; onset more frequent during first 6 months of therapy; sinterruption and\/or infusion time adjustment may be necessary; consider pre-treatment with antihistamines and\/or corticosteroids if symptoms occurred with prior use<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929595-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"929595-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929595-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (15% to 19%), Nausea (6% to 10%)<\/li><li><b>Hematologic:<\/b>Partial thromboplastin time increased (5% to 11%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (Enzyme replacement therapy naive, 52%; switched from imiglucerase, 23%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Knee (8% to 15%), Backache (17% to 18%)<\/li><li><b>Neurologic:<\/b>Asthenia, Dizziness (Enzyme replacement therapy naive, 22%; switched from imiglucerase, 8%), Headache (30% to 35%)<\/li><li><b>Other:<\/b>Fatigue, Fever (13% to 22%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis<br\/>"},"6":{"id":"929595-s-6","title":"Drug Name Info","sub":{"0":{"id":"929595-s-6-17","title":"US Trade Names","mono":"VPRIV<br\/>"},"2":{"id":"929595-s-6-19","title":"Class","mono":"<ul><li>Enzyme<\/li><li>Enzyme Replacement<\/li><\/ul>"},"3":{"id":"929595-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929595-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929595-s-7","title":"Mechanism Of Action","mono":"Velaglucerase alfa, an enzyme created by gene activation technology in human fibroblast cells, catalyzes hydrolysis of glucocerebroside. In patients deficient in lysosomal enzyme beta-glucocerebrosidase (Gaucher disease), velaglucerase alfa will catalyze conversion of sphingolipid glucocerebroside into glucose and ceramide, thereby reducing the accumulation of glucocerebroside in the lysosomal compartment of macrophages (Gaucher cells) and subsequent accumulation of Gaucher cells in the liver, spleen, bone marrow and other organs.<br\/>"},"8":{"id":"929595-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"929595-s-8-24","title":"Distribution","mono":"Vd: 82 to 108 mL\/kg <br\/>"},"3":{"id":"929595-s-8-26","title":"Excretion","mono":"Total body clearance: 6.72 to 7.56 mL\/min\/kg <br\/>"},"4":{"id":"929595-s-8-27","title":"Elimination Half Life","mono":"11 to 12 min <br\/>"}}},"9":{"id":"929595-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute with sterile water for injection by gently mixing vials to an initial concentration of 100 units\/mL (do not shake); further dilute reconstituted solution in 100 mL NS<\/li><li>slight flocculation may occur in diluted solution, but solution is still acceptable for administration<\/li><li>discard unused solution after 24 hours<\/li><li>for IV use only; infuse through an inline low protein-binding 0.2-micron filter over 60 minutes<\/li><li>do not infuse with other products in the same tubing<\/li><li>complete infusion within 24 hours of reconstitution of vials<\/li><\/ul>"},"10":{"id":"929595-s-10","title":"Monitoring","mono":"<ul><li>normalization of hemoglobin and platelet counts is indicative of efficacy<\/li><li>reduction in liver and spleen enlargement is indicative of efficacy<\/li><\/ul>"},"11":{"id":"929595-s-11","title":"How Supplied","mono":"<b>VPRIV<\/b><br\/>Intravenous Powder for Solution: 400 U<br\/>"},"13":{"id":"929595-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause infusion reactions during or up to 24 hours after infusion that include hypotension or hypertension.<\/li><li>This drug may cause headache, dizziness, abdominal pain, nausea, and fever.<\/li><\/ul>"}}}